Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 115

Similar articles for PubMed (Select 20607654)

1.

A role for mammalian target of rapamycin (mTOR) pathway in non alcoholic steatohepatitis related-cirrhosis.

Kubrusly MS, Corrêa-Giannella ML, Bellodi-Privato M, de Sá SV, de Oliveira CP, Soares IC, Wakamatsu A, Alves VA, Giannella-Neto D, Bacchella T, Machado MC, D'Albuquerque LA.

Histol Histopathol. 2010 Sep;25(9):1123-31.

PMID:
20607654
2.

Decreased immunoexpression of survivin could be a potential marker in human non-alcoholic fatty liver disease progression?

Stefano JT, de Oliveira CP, Corrêa-Giannella ML, Soares IC, Kubrusly MS, Bellodi-Privato M, de Mello ES, de Lima VM, Carrilho FJ, Alves VA.

Liver Int. 2011 Mar;31(3):377-85. doi: 10.1111/j.1478-3231.2010.02370.x. Epub 2010 Nov 26.

PMID:
21108736
3.

Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis.

Younossi ZM, Gorreta F, Ong JP, Schlauch K, Del Giacco L, Elariny H, Van Meter A, Younoszai A, Goodman Z, Baranova A, Christensen A, Grant G, Chandhoke V.

Liver Int. 2005 Aug;25(4):760-71.

PMID:
15998427
4.

Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.

Zhou X, Tan M, Stone Hawthorne V, Klos KS, Lan KH, Yang Y, Yang W, Smith TL, Shi D, Yu D.

Clin Cancer Res. 2004 Oct 15;10(20):6779-88.

5.

The FLS (fatty liver Shionogi) mouse reveals local expressions of lipocalin-2, CXCL1 and CXCL9 in the liver with non-alcoholic steatohepatitis.

Semba T, Nishimura M, Nishimura S, Ohara O, Ishige T, Ohno S, Nonaka K, Sogawa K, Satoh M, Sawai S, Matsushita K, Imazeki F, Yokosuka O, Nomura F.

BMC Gastroenterol. 2013 Jul 23;13:120. doi: 10.1186/1471-230X-13-120.

6.

Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors.

Xu G, Zhang W, Bertram P, Zheng XF, McLeod H.

Int J Oncol. 2004 Apr;24(4):893-900.

PMID:
15010827
7.

Systematic analysis of the gene expression in the livers of nonalcoholic steatohepatitis: implications on potential biomarkers and molecular pathological mechanism.

Zhang Y, Baker SS, Baker RD, Zhu R, Zhu L.

PLoS One. 2012;7(12):e51131. doi: 10.1371/journal.pone.0051131. Epub 2012 Dec 26.

8.

Multi-SNP analysis of GWAS data identifies pathways associated with nonalcoholic fatty liver disease.

Chen QR, Braun R, Hu Y, Yan C, Brunt EM, Meerzaman D, Sanyal AJ, Buetow K.

PLoS One. 2013 Jul 19;8(7):e65982. doi: 10.1371/journal.pone.0065982. Print 2013.

9.

Expression of cytokine signaling genes in morbidly obese patients with non-alcoholic steatohepatitis and hepatic fibrosis.

Estep JM, Baranova A, Hossain N, Elariny H, Ankrah K, Afendy A, Chandhoke V, Younossi ZM.

Obes Surg. 2009 May;19(5):617-24. doi: 10.1007/s11695-009-9814-x. Epub 2009 Mar 12.

PMID:
19280268
10.

Gene expression profiling unravels cancer-related hepatic molecular signatures in steatohepatitis but not in steatosis.

Starmann J, Fälth M, Spindelböck W, Lanz KL, Lackner C, Zatloukal K, Trauner M, Sültmann H.

PLoS One. 2012;7(10):e46584. doi: 10.1371/journal.pone.0046584. Epub 2012 Oct 10.

11.
12.

Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas.

Korkolopoulou P, Levidou G, El-Habr EA, Piperi C, Adamopoulos C, Samaras V, Boviatsis E, Thymara I, Trigka EA, Sakellariou S, Kavantzas N, Patsouris E, Saetta AA.

Histopathology. 2012 Aug;61(2):293-305. doi: 10.1111/j.1365-2559.2012.04236.x. Epub 2012 Jun 13.

PMID:
22690797
13.

Molecular interplay between Δ5/Δ6 desaturases and long-chain fatty acids in the pathogenesis of non-alcoholic steatohepatitis.

López-Vicario C, González-Périz A, Rius B, Morán-Salvador E, García-Alonso V, Lozano JJ, Bataller R, Cofán M, Kang JX, Arroyo V, Clària J, Titos E.

Gut. 2014 Feb;63(2):344-55. doi: 10.1136/gutjnl-2012-303179. Epub 2013 Mar 14.

PMID:
23492103
14.
15.

SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease.

Kohjima M, Higuchi N, Kato M, Kotoh K, Yoshimoto T, Fujino T, Yada M, Yada R, Harada N, Enjoji M, Takayanagi R, Nakamuta M.

Int J Mol Med. 2008 Apr;21(4):507-11.

PMID:
18360697
16.

Characterization of hepatocellular carcinoma related genes and metabolites in human nonalcoholic fatty liver disease.

Clarke JD, Novak P, Lake AD, Shipkova P, Aranibar N, Robertson D, Severson PL, Reily MD, Futscher BW, Lehman-McKeeman LD, Cherrington NJ.

Dig Dis Sci. 2014 Feb;59(2):365-74. doi: 10.1007/s10620-013-2873-9. Epub 2013 Sep 19.

17.

Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma.

Pópulo H, Soares P, Rocha AS, Silva P, Lopes JM.

Melanoma Res. 2010 Apr;20(2):107-17. doi: 10.1097/CMR.0b013e32832ccd09.

PMID:
20173664
18.

Genome-wide transcriptome analysis identifies novel gene signatures implicated in human chronic liver disease.

Smalling RL, Delker DA, Zhang Y, Nieto N, McGuiness MS, Liu S, Friedman SL, Hagedorn CH, Wang L.

Am J Physiol Gastrointest Liver Physiol. 2013 Sep 1;305(5):G364-74. doi: 10.1152/ajpgi.00077.2013. Epub 2013 Jun 27.

19.

[Gene expression in obese patients with non-alcoholic steatohepatitis].

Cayón A, Crespo J, Guerra AR, Pons-Romero F.

Rev Esp Enferm Dig. 2008 Apr;100(4):212-8. Spanish.

20.

The Akt/mammalian target of rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomas.

Setsu N, Yamamoto H, Kohashi K, Endo M, Matsuda S, Yokoyama R, Nishiyama K, Iwamoto Y, Dobashi Y, Oda Y.

Cancer. 2012 Mar 15;118(6):1637-48. doi: 10.1002/cncr.26448. Epub 2011 Aug 11.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk